Company intelligence / Profile preview

Neurocords

Ownership: Private
Development stage: Other

Overview

Neurocords developed technology to differentiate induced pluripotent stem cells (iPSC) into spinal cord neurons for spinal cord injury (SCI) regenerative medicine; platform and key assets were acquired by Orgenesis in March 2025. Technology is not yet clinically validated or commercialized, but integration aims to improve manufacturing scalability and reduce treatment costs.[1][2]

Therapeutic areas: Neurology
Modalities: Induced pluripotent stem cell derived therapyCell therapy
Industry: Biotech

Partnerships

OrgenesisVeterans Administration (VA) clinical network

Beyond the preview

Go deeper on Neurocords.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurocords.

Explore the full profile